89 related articles for article (PubMed ID: 23190580)
1. Hsp90 - a potential prognostic marker in CML.
Záčková M; Moučková D; Lopotová T; Ondráčková Z; Klamová H; Moravcová J
Blood Cells Mol Dis; 2013 Mar; 50(3):184-9. PubMed ID: 23190580
[TBL] [Abstract][Full Text] [Related]
2. CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease.
Gonzalez M; De Brasi C; Ferri C; Bengió R; Bianchini M; Larripa I
Leuk Lymphoma; 2014 Sep; 55(9):2101-8. PubMed ID: 24206096
[TBL] [Abstract][Full Text] [Related]
3. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
4. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
[TBL] [Abstract][Full Text] [Related]
5. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
6. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
7. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
8. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
Pocaly M; Lagarde V; Etienne G; Ribeil JA; Claverol S; Bonneu M; Moreau-Gaudry F; Guyonnet-Duperat V; Hermine O; Melo JV; Dupouy M; Turcq B; Mahon FX; Pasquet JM
Leukemia; 2007 Jan; 21(1):93-101. PubMed ID: 17109025
[TBL] [Abstract][Full Text] [Related]
10. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
11. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
13. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
14. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
Na IK; Kreuzer KA; Lupberger J; Dörken B; le Coutre P
Leuk Res; 2005 Mar; 29(3):343-5. PubMed ID: 15661271
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization and prognostic significance of FLT3 in CML progression.
Kim KI; Park J; Ahn KS; Won NH; Kim BK; Shin WG; Yoon SS; Oh JM
Leuk Res; 2010 Aug; 34(8):995-1001. PubMed ID: 20031210
[TBL] [Abstract][Full Text] [Related]
16. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
18. Significance of FHIT expression in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M
Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340
[TBL] [Abstract][Full Text] [Related]
19. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman JU; Kurzrock R
Leukemia; 1991 Mar; 5(3):191-5. PubMed ID: 2013978
[TBL] [Abstract][Full Text] [Related]
20. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
